MedTrace Logo

Dose-Proportionality and Food Effect Study of TNX-102 SL

NCT04164719 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-01-06

No results posted yet for this study

Summary

This will be a single center, single-dose, randomized, open-label, 3-period, crossover, dose-proportionality and food-effect study.

Conditions

  • Healthy Subjects

Interventions

DRUG

TNX-102 SL

Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them

Sponsors & Collaborators

  • Tonix Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Denis Audet, MD · Contract Research Organization

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-14
Primary Completion
2019-12-24
Completion
2019-12-24
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04164719 on ClinicalTrials.gov